Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions
Venlafaxine XR, Aerobic Exercise, Lorazepam
Drug · Other
Lead sponsor
Kirk Erickson, PhD
Other
Eligibility
60 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Depression, Anxiety, Fear, Depression, Anxiety and Fear, Anxiety Disorders, Anxious Depression
Interventions
Lorazepam, Placebo
Drug · Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Healthy Subjects
Interventions
placebo, lorazepam, GW876008
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
La Jolla, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Depressive Disorder and Anxiety Disorders
Interventions
single dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
La Jolla, California